EXEL - Exelixis begins late-stage study of XL092 to treat colorectal cancer subtype

Exelixis (NASDAQ:EXEL) said it began a phase 3 trial of XL092 in combination with Roche's (OTCQX:RHHBY) (OTCQX:RHHBF) Tecentriq (atezolizumab) versus Bayer's (OTCPK:BAYRY) (OTCPK:BAYZF) Stivarga (regorafenib) in patients with metastatic colorectal cancer which is not microsatellite instability-high or mismatch repair-deficient, who have progressed after or are intolerant to the standard of care therapy. XL092 is a next-generation tyrosine kinase inhibitor (TKI) in development for multiple advanced tumor types, the company said in a June 21 press release. The study, dubbed STELLAR-303, will enroll ~600 patients with documented RAS status. "Following recent promising data evaluating cabozantinib in combination with immunotherapies in colorectal cancer, we are thrilled to initiate our first phase 3 pivotal trial for XL092, our next-generation tyrosine kinase inhibitor," said said Vicki Goodman, executive vice president, product development & medical affairs, and chief medical officer, Exelixis.

For further details see:

Exelixis begins late-stage study of XL092 to treat colorectal cancer subtype